Compare And Contrast Tumour Suppressor Genes And Proto-Oncogenes
Some of these viruses were notable due to the simplicity of their RNA genome. These viruses only had three distinct transcription units, involved in the replication of the virus (coat proteins and reverse transcriptase etc.), and an extra gene. This was an oncogene. When oncogenes are properly functioning they are termed proto-oncogenes (Todd R, 1999). Their normal function is to control cell proliferation. These function in growth signalling pathways, and conversely to tumour suppressing cells are activated through a gain in function rather than a loss of it. This occurs in two ways, by producing more of a product, or producing a subtly different product, as a result of a mutation similar to tumour suppressor genes (Croce, 2008). Oncogenes play a particularly strong role in the development of breast cancers. Often the normal ERBB2 and other related genes are amplified in late stage neuroblastomas and rhabdomyosarcomas. ERBB2 encodes HER2 which is a member of the epidermal growth factor receptor, and a factor in 30% of all breast …show more content…
2007. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 4036 - 41
CROCE, C. M. 2008. Oncogenes and Cancer. The New England Journal of Medicine, 358, 502 - 11.
FLECK, L. 2006. The costs of caring: Who pays? Who profits? Who panders? . Hastings Central Report, 36, 13 - 17.
HYUN-SOO CHO, E. A. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature Reviews Cancer, 421, 756 - 760.
JEMAL, A. 2011. Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69 - 90.
KNUDSON, A. G. 1971. Mutation and Cancer: Statistical Study of Retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68, 820 - 823.
KNUDSON, A. G. 2001. Two Genetic Hits (More or Less) to Cancer. Nature Reviews Cancer, 1, 157 - 162.
MOLINA, M. A. & ET-AL 2001. Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Research, 61,